<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02655562</url>
  </required_header>
  <id_info>
    <org_study_id>Beijing Chao Yang Hospital</org_study_id>
    <nct_id>NCT02655562</nct_id>
  </id_info>
  <brief_title>Fractional Concentration of Exhaled NO(FeNO) to Direct The Treatment of Sub-acute Cough</brief_title>
  <official_title>Fractional Concentration of Exhaled NO(FeNO) to Direct The Treatment of Sub-acute Cough：A Prospective, Open Label, Randomized and Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cough is a common symptom that leads patients worldwide to seek medical attention. Subacute
      cough refers to a cough of 3-8-week duration, and is typically refractory to standard
      anti-tussive therapy, and a tendency to spontaneous healing was common. Few clinical trials
      have evaluated therapeutic options for subacute cough. Airway inflammation is an important
      feature of most of subacute cough, Cysteinyl leukotrienes and FeNO correlates with airway
      inflammation. Subacute cough often represents a prolonged post-viral response. Cysteinyl
      leukotrienes increase in virus infection. Airway inflammation induce epithelial cells produce
      iNOS(inducible nitric oxide synthase,iNOS), and FeNO increase in theory. Montelukast is a
      cysteinyl leukotriene type 1 receptor antagonist that is reported to improve cough16 and
      reduces FENO and prevents increases in FENO during reduction of inhaled corticosteroid dose,
      But A meta-analysis of the effectiveness of LTRA( leukotriene receptor antagonist,LTRA)in
      treating children with prolonged non-specific cough concluded that, with the lack of
      evidence, the routine use of LTRA in treating children with non-specific cough cannot be
      recommended. A randomised, placebo-controlled trial showed montelukast is not an effective
      treatment for postinfectious cough. Non-specialists or general practitioners of Japan
      prescribe LTRA very often, which increase. The aim is to research whether FeNO can be used as
      a biomarker to direct montelukast treatment and optimize treatment regimen of sub-acute
      cough.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is a prospective, open label, randomized and controlled trial. All subacute
      cough patients that met the inclusion/exclusion criteria were recruited after signing the
      consent form. Patients were randomized into biomarker treatment armand standard treatment
      arm.

      Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets
      (p.o., 10mg, q.d.) . Patients in biomarker reatment arm and FENO＜25ppb were given placebo
      (p.o., 10mg, qd). Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o.,
      10mg, qd). Patients in standard treatment arm and FENO＜25ppb were given Montelukast Sodium
      Tablets (p.o., 10mg, q.d.) .All treatment regimens lasted for 10 days and no other
      antitussive/decongestant or bronchodilators are given to any patients.

      Examine results of all patients from all arms were recorded before and after the 10 day
      treatment. The examine recorded are FENO levels, cough symptom assessment, cough visual
      assessment, Leicester cough questionnaire, total white blood cell count, neutrophil blood
      percentage, eosinophil blood percentage. Patient cough free days after treatment and
      Montelukast Sodium Tablets . Follow up was carried out at the 8th week after first record of
      symptom and 2 month after treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Leicester cough questionnaire</measure>
    <time_frame>10 days</time_frame>
    <description>Change in Leicester Cough Questionnaire(LCQ) total and domain scores at 10 days post randomisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cough visual assessment</measure>
    <time_frame>10 days</time_frame>
    <description>Change in Leicester Cough Questionnaire(LCQ) physical,psychological and social domain scores at 10 days post randomisation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coughing</condition>
  <arm_group>
    <arm_group_label>biomarker treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO＜25ppb were given placebo (p.o., 10mg, qd).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard treatment arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO＜25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO＜25ppb were given placebo (p.o., 10mg, qd).
Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO＜25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.</description>
    <arm_group_label>biomarker treatment arm</arm_group_label>
    <arm_group_label>standard treatment arm</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cough is the main or only clinical symptom and was persistent for 3-8 weeks Chest
             X-ray reveals no noticeable pathological changes

          -  more than 18 year old, regardless of gender and ethical background

          -  Not taking angiotensin-converting enzyme inhibitor

          -  Patients must join the programme voluntarily and are able to attend examination and
             follow-up sessions

        Exclusion Criteria:

          -  Patients diagnosed with allergic rhinitis, chronic nasosinusitis or bacterial
             respiratory tract infections

          -  Patients diagnosed with severe reportorial disease of other severe systemic disease

          -  Patients who are allergic to any drugs to be tested

          -  Patients who are non-cooperative during examination sessions or other steps of the
             trial

          -  Patients who are not able to or refuse to sign consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kewu Huang, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Respiratory Medicine Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mingming Jiang, Doctor</last_name>
    <phone>15350771390</phone>
    <email>jmmsh@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kewu Huang, M.D.</last_name>
    <phone>86-10-85231167</phone>
    <email>kewuhuang@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mingming Jiang</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingming Jiang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wedde-Beer K, Hu C, Rodriguez MM, Piedimonte G. Leukotrienes mediate neurogenic inflammation in lungs of young rats infected with respiratory syncytial virus. Am J Physiol Lung Cell Mol Physiol. 2002 May;282(5):L1143-50.</citation>
    <PMID>11943681</PMID>
  </reference>
  <reference>
    <citation>van Schaik SM, Tristram DA, Nagpal IS, Hintz KM, Welliver RC 2nd, Welliver RC. Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing. J Allergy Clin Immunol. 1999 Apr;103(4):630-6.</citation>
    <PMID>10200012</PMID>
  </reference>
  <reference>
    <citation>Spector SL, Tan RA. Effectiveness of montelukast in the treatment of cough variant asthma. Ann Allergy Asthma Immunol. 2004 Sep;93(3):232-6.</citation>
    <PMID>15478381</PMID>
  </reference>
  <reference>
    <citation>Kato A, Schleimer RP. Beyond inflammation: airway epithelial cells are at the interface of innate and adaptive immunity. Curr Opin Immunol. 2007 Dec;19(6):711-20. Epub 2007 Oct 24. Review.</citation>
    <PMID>17928212</PMID>
  </reference>
  <reference>
    <citation>Mincheva RK, Kralimarkova TZ, Rasheva M, Dimitrov Z, Nedeva D, Staevska M, Papochieva V, Perenovska P, Bacheva K, Dimitrov VD, Popov TA. A real - life observational pilot study to evaluate the effects of two-week treatment with montelukast in patients with chronic cough. Cough. 2014 Mar 20;10(1):2. doi: 10.1186/1745-9974-10-2.</citation>
    <PMID>24649919</PMID>
  </reference>
  <reference>
    <citation>Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003 Apr;58(4):339-43.</citation>
    <PMID>12668799</PMID>
  </reference>
  <reference>
    <citation>Sandrini A, Ferreira IM, Gutierrez C, Jardim JR, Zamel N, Chapman KR. Effect of montelukast on exhaled nitric oxide and nonvolatile markers of inflammation in mild asthma. Chest. 2003 Oct;124(4):1334-40.</citation>
    <PMID>14555563</PMID>
  </reference>
  <reference>
    <citation>Wang K, Birring SS, Taylor K, Fry NK, Hay AD, Moore M, Jin J, Perera R, Farmer A, Little P, Harrison TG, Mant D, Harnden A. Montelukast for postinfectious cough in adults: a double-blind randomised placebo-controlled trial. Lancet Respir Med. 2014 Jan;2(1):35-43. doi: 10.1016/S2213-2600(13)70245-5. Epub 2013 Dec 2.</citation>
    <PMID>24461900</PMID>
  </reference>
  <results_reference>
    <citation>Kwon NH, Oh MJ, Min TH, Lee BJ, Choi DC. Causes and clinical features of subacute cough. Chest. 2006 May;129(5):1142-7.</citation>
    <PMID>16685003</PMID>
  </results_reference>
  <results_reference>
    <citation>Lim KG, Mottram C. The use of fraction of exhaled nitric oxide in pulmonary practice. Chest. 2008 May;133(5):1232-42. doi: 10.1378/chest.07-1712. Review.</citation>
    <PMID>18460522</PMID>
  </results_reference>
  <results_reference>
    <citation>Tárnoky AL. Albumin. Ann Clin Biochem. 1981 Mar;18 (Pt 2):61-3.</citation>
    <PMID>7259071</PMID>
  </results_reference>
  <results_reference>
    <citation>Sato S, Saito J, Sato Y, Ishii T, Xintao W, Tanino Y, Ishida T, Munakata M. Clinical usefulness of fractional exhaled nitric oxide for diagnosing prolonged cough. Respir Med. 2008 Oct;102(10):1452-9. doi: 10.1016/j.rmed.2008.04.018. Epub 2008 Jul 9.</citation>
    <PMID>18614345</PMID>
  </results_reference>
  <results_reference>
    <citation>Tamaoki J, Kondo M, Sakai N, Nakata J, Takemura H, Nagai A, Takizawa T, Konno K. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit Care Med. 1997 Apr;155(4):1235-40.</citation>
    <PMID>9105060</PMID>
  </results_reference>
  <results_reference>
    <citation>Morice AH, Fontana GA, Sovijarvi AR, Pistolesi M, Chung KF, Widdicombe J, O'Connell F, Geppetti P, Gronke L, De Jongste J, Belvisi M, Dicpinigaitis P, Fischer A, McGarvey L, Fokkens WJ, Kastelik J; ERS Task Force. The diagnosis and management of chronic cough. Eur Respir J. 2004 Sep;24(3):481-92. Review.</citation>
    <PMID>15358710</PMID>
  </results_reference>
  <results_reference>
    <citation>Gentile DA, Fireman P, Skoner DP. Elevations of local leukotriene C4 levels during viral upper respiratory tract infections. Ann Allergy Asthma Immunol. 2003 Sep;91(3):270-4.</citation>
    <PMID>14533659</PMID>
  </results_reference>
  <results_reference>
    <citation>Grant CC. Postinfectious cough and pertussis in primary care. Lancet Respir Med. 2014 Jan;2(1):2-3. doi: 10.1016/S2213-2600(13)70260-1. Epub 2013 Dec 2.</citation>
    <PMID>24461880</PMID>
  </results_reference>
  <results_reference>
    <citation>Dahlén SE. Treatment of asthma with antileukotrienes: first line or last resort therapy? Eur J Pharmacol. 2006 Mar 8;533(1-3):40-56. Epub 2006 Feb 28. Review.</citation>
    <PMID>16510137</PMID>
  </results_reference>
  <results_reference>
    <citation>Dicpinigaitis PV. Cough: an unmet clinical need. Br J Pharmacol. 2011 May;163(1):116-24. doi: 10.1111/j.1476-5381.2010.01198.x. Review.</citation>
    <PMID>21198555</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2015</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <last_update_submitted>August 25, 2016</last_update_submitted>
  <last_update_submitted_qc>August 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Mingming Jiang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Bronchodilator Agents</mesh_term>
    <mesh_term>Nasal Decongestants</mesh_term>
    <mesh_term>Antitussive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

